Find a Commonwealth Resource
Quizartinib
HealthData.Gov
Updated Jul 6, 2026
About this dataset
VANFLYTA (quizartinib) is an oral prescription tablet developed by Daiichi Sankyo Inc. for treating certain blood cancers. It works as a kinase inhibitor targeting FLT3 mutations, available in 17.7 mg and 26.5 mg strengths. This information was generated using AI and is provided for informational and research purposes only.
Data and resources (1)
- HTML
Quizartinib
Access the FDA dataset for Quizartinib — ANDA 203308 submitted by Mylan Institutional LLC
Modified Mar 23, 2026